



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** April 4, 2008

**To:** Primary Clinical Research Associates

**From:** Sara Braun  
Protocol Development Coordinator

**Re:** N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

This study was approved by the National Cancer Institute on October 16, 2007.

Please note, the Phase I portion of this study will open to Mayo Rochester and Mayo Jacksonville sites only. Upon completion of Phase I, the Phase II portion of the study will be opened to all NCCTG sites.

If you have any questions, please feel free to contact me.

Enclosure